a. How could you use sequence analysis to determine if this patient inherited the mutation from one of her parents or if it spontaneously occurred in her cells? (Unfortunately her parents have passed away.) b. How could you use sequence analysis to determine if this gene is a tumor suppressor or an oncogene? (For partial credit briefly define tumor suppressor and oncogene.)

a. How could you use sequence analysis to determine if this patient inherited the mutation from one of her parents or if it spontaneously occurred in her cells? (Unfortunately her parents have passed away.) b. How could you use sequence analysis to determine if this gene is a tumor suppressor or an oncogene? (For partial credit briefly define tumor suppressor and oncogene.)

Human Heredity: Principles and Issues (MindTap Course List)

11th Edition

ISBN:9781305251052

Author:Michael Cummings

Publisher:Michael Cummings

Chapter15: Genomes And Genomics

Section: Chapter Questions

Problem 14QP

See similar textbooks

Similar questions

The search for the BRCA1 breast cancer gene discussed in this chapter was widely publicized in the media (for example, Newsweek, December 6, 1993). Describe the steps taken by Mary-Claire King and her colleagues to clone this gene. How long did this process take?
Two genes associated with breast cancer, BRCA1 and BRCA2, were discovered in 1994 and 1995, respectively, and shortly thereafter, were patented by Myriad Genetics, a company based in Utah. Under the patents, testing for mutations in these genes could only be performed by Myriad, at costs from 300 to 3,000. Myriad also patented the process of analyzing the results of such tests, preventing anyone who obtains the sequence of their BRCA genes by other means (which itself would probably be patent infringement) from interpreting the information. The idea that genes can be patented has been a contentious issue from the beginning. Patents are not granted for products of nature, meaning that genes inside the body are not patentable, but biotech companies successfully argued that by removing a gene from the human body, purifying it, and then obtaining its DNA sequence, they created something not found in nature, and which is therefore a patentable invention. The U.S. Patent Office found the argument persuasive, but opponents argue that genes are parts of our bodies and can be identified but not invented. Biotech companies argue that without the protection offered by patents, they would have no incentive for research and development of diagnostic tests. In Europe, patents for BRCA1 and BRCA2 were revoked in 2004 because they did not meet the standards for a patent. After more than a decade of legal disputes, the patents were partially restored in 2008 on a very restricted basis. In the United States, a lawsuit, focused on the patents for the BRCA genes, was filed in May 2009. The suit challenges the basic idea that genes are patentable. In November 2009, the judge ruled that the lawsuit can proceed, and the case is moving forward. In March 2010, a federal court invalidated Myriad Genetics patent on these genes. In August 2011, the U.S. Court of Appeals reversed the lower courts decision and ruled that gene sequences isolated from cells are not a product of nature and are therefore patentable. The case went to the U.S. Supreme Court, which ordered the appeals court to reconsider the case. The Federal Appeals Court did not change its decision, and the case once again, went to the U.S. Supreme Court. A unanimous decision in June 2013 invalidated Myriads patents on the basis that isolating a gene from nature does not make it patentable. This is a landmark decision on gene patenting with widespread ramifications for the biotechnoloogy industry. Will this decision reduce the incentives for companies to invest in new diagnostic tests that would be used by cancer victims or those with serious genetic disorders?
A woman has just been diagnosed with breast cancer. Her doctor tells her that while cancer is a multifactorial disease, she carries the breast cancer susceptibility gene, BRCA1. One of her two identical twin 19-year-old daughters is afraid that she also may have inherited the gene.-What considerations would you give her daughter who is worried about inheriting the cancer gene?
On the image, you can see the results of a DNA microarray used for cancer prognosis, where tissue samples from healthy and cancerous tissues were analyzed. cDNA from healthy cells and cancer cells were labeled with green and red fluorescence, respectively, mixed equally, and hybridized with the chip. It is known that gene A is more highly expressed in breast cancer type I, while genes B and C have lower expression in type II, which is highly aggressive. Based on the gene expression levels shown in the image, the cancer sample does not correspond to either type I or type II breast cancer, why is that?
1- You are studying lung cancer and use a microarray to compare gene expression between a lung cancer tumor and healthy adjacent lung tissue. If you label vour cancer cDNAwith red fiuorescence and your normal tissue with green, what color would you expect tumor suppressors to be:© a. GreenU D. RedOc.No color) d. Either Red or Green© e Yellow 2- You want to study histone modifications using Next Generation sequencing. What technique would allow you to do this?© a, Sanger sequencing© b. Fluorescence in situ hybl© c. RNA-SeqOld. ChIP-sed© e. Poymerase Chain Reaction 3-Gertrudae mcfuzzi is a rare (and ficticious) species of bird with colorful tail feathers. All Gertrude mcfuzzi develop 1 tail feather when they are born, and can grow additionaltall teathers during matunty depending on the alleles they inherit at a number of additive loci (T, S, and G) which form the geise/-complex. Each positive (+) allele adds one lalfeather and each negative - allele produces no additional feathers, based…
What are the biggest challenges that mutations pose to oncologists and cancer biologists who seek to find novel cures against cancers?
Can we treat cancer by restoring tumor suppressor function such as mutated p53 or pRb? If so, how can this be?
Why does a single mutation in a proto-oncogene, turning it into an oncogene potentially lead to a cancerous phenotype, while it takes two mutations in tumor suppressor genes to lead to a cancerous phenotype?
Mutations in the CFTR gene result in cystic fibrosis in humans, a conditions in which abnormal secretions are present in the lungs, pancreas, and sweat glands. The gene was mapped to a 500-kb region on chromosome 7 containing 3 candidate genes. a)Using your knowledge of the disease symptoms, how would you distinguish between the candidate genes to decide which is most likely to encode the CFTR gene? b)How would you prove that your chosen candidate is the CFTR gene?
Let’s suppose you were interested in developing drugs to preventepigenetic changes that may contribute to cancer. What cellularproteins would be the target of your drugs? What possible sideeffects might your drugs cause?
Define about this- Cancer Cells Contain GeneticDefects Affecting Genomic Stability ?
In the treatment of cancer, the basis for many types of chemotherapyand radiation therapy is that mutagens are more effective at killingdividing cells than nondividing cells. Explain why. What are possibleharmful side effects of chemotherapy and radiation therapy?